Introduction Radioiodine (131I-Nal) is used widely in the management of differentiated
thyroid cancer, to achieve thyroid remnant ablation, as an adjuvant treatment to reduce the …

Although most patients with metastatic or inoperable locally recurrent differentiated thyroid
cancer have radioiodine-avid disease, the outcome for patients who do not achieve …

Thefirst reports of radionuclide therapy for thyroid disease used 130I, but 131I rapidly
became the favoured radionuclide with beta-and gamma-ray emissions and a half-life …

Although differentiated thyroid cancers are not common, they are as common as cervical
cancer and multiple myeloma and are the commonest malignant endocrine tumours …

Although radioiodine for the treatment of differentiated thyroid cancer is most commonly
given as a fixed, empirical activity, it is well recognised that this leads to a wide range of …

Thyroid nodular disease is common in the UK (8.6%) and 50% of nodules are considered
solitary. They are more common in women and the problem increases with age. Although …

The “Guidelines for the Management of Thyroid Cancer” 2nd edition, by the British Thyroid
Association and the Royal College of Physicians, has been updated 5 years after the …

This book is intended for practitioners who manage patients with thyroid cancer and
students who are learning about the disease. It aims to provide practical information about …

Background International guidelines on the treatment of differentiated thyroid cancers
promote low iodine diets (LID) before radioiodine remnant ablation. Evidence that the LID …

This paper analyzes the available data on the dosimetric approach and describes the use of
dosimetry in the Division of Nuclear Medicine of the National Cancer Institute in Milan …